The marked upregulation of PSMA in the “pseudohypoxia driven” Cluster 1 PPGLs with pathogenic SDHB, VHL, or EPAS1 mutations opens a new door toward the existing theranostic application of already formulated and approved PSMA-targeted radioligands utilized in metastatic castration-resistant prostate cancer. The gene discussed is EPAS1; the disease is Familial prostate cancer.